Published in J Clin Gastroenterol on December 16, 2004
A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet (2009) 5.29
Evidence-based clinical guidelines for immigrants and refugees. CMAJ (2010) 3.57
Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect (2010) 3.35
Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol (2011) 2.37
Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut (2008) 1.86
Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis (2013) 1.65
Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. PLoS One (2012) 1.56
Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact (2011) 1.44
Sero-prevalence and risk factors for hepatitis B virus infection among health care workers in a tertiary hospital in Uganda. BMC Infect Dis (2010) 1.34
KIR/HLA interactions and pathogen immunity. J Biomed Biotechnol (2011) 1.26
The impact of differential antiviral immunity in children and adults. Nat Rev Immunol (2012) 1.21
The burden of liver cancer in Asians and Pacific Islanders in the Greater San Francisco Bay Area, 1990 through 2004. Cancer (2007) 1.21
Seroprevalence of hepatitis B and C viruses among medical waste handlers at Gondar town Health institutions, Northwest Ethiopia. BMC Res Notes (2012) 1.19
Epidemiologic study of chronic hepatitis B virus infection in male volunteer blood donors in Karachi, Pakistan. BMC Gastroenterol (2005) 1.18
New loci associated with chronic hepatitis B virus infection in Han Chinese. Nat Genet (2013) 1.18
A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance in Han Chinese. J Infect Dis (2011) 1.17
Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States. J Urban Health (2008) 1.17
Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J Gastroenterol (2011) 1.14
Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B. Dig Dis Sci (2014) 1.13
An assessment of the effect of hepatitis B vaccine in decreasing the amount of hepatitis B disease in Italy. Virol J (2008) 1.13
The impact of hepatitis B knowledge and stigma on screening in Canadian Chinese persons. Can J Gastroenterol (2012) 1.12
Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One (2012) 1.08
Management of hepatitis B in developing countries. World J Hepatol (2011) 1.08
Hepatitis B and liver cancer knowledge and practices among healthcare and public health professionals in China: a cross-sectional study. BMC Public Health (2010) 1.05
Factors Correlated With Hepatitis C and B Virus Infections Among Injecting Drug Users in Tehran, IR Iran. Hepat Mon (2012) 1.03
Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol (2012) 1.03
Electronic messages increase hepatitis B screening in at-risk Asian American patients: a randomized, controlled trial. Dig Dis Sci (2012) 1.03
Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B. World J Gastroenterol (2012) 1.01
The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. PLoS One (2014) 1.01
Targeting autophagy for the treatment of liver diseases. Pharmacol Res (2012) 1.01
Hepatocellular carcinoma: A comprehensive review. World J Hepatol (2015) 0.98
Common genotypes of Hepatitis B virus prevalent in injecting drug abusers (addicts) of North West Frontier Province of Pakistan. Virol J (2007) 0.98
Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions. World J Gastroenterol (2014) 0.98
Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol (2012) 0.97
Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States. J Subst Abuse Treat (2011) 0.96
Occult hepatitis B virus infection: A major concern in HIV-infected patients: Occult HBV in HIV. Hepat Mon (2011) 0.95
Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. PLoS One (2013) 0.95
Risk factors for hepatitis B infection in rural Vietnam. Asian Pac J Cancer Prev (2009) 0.95
Hepatitis B prevention and control: Lessons from the East and the West. World J Hepatol (2011) 0.95
Glucose-regulated protein 78 is an intracellular antiviral factor against hepatitis B virus. Mol Cell Proteomics (2009) 0.93
Molecular analysis of hepatitis B virus isolates in Mexico: predominant circulation of hepatitis B virus genotype H. World J Gastroenterol (2006) 0.93
Spatial and temporal dynamics of hepatitis B virus D genotype in Europe and the Mediterranean Basin. PLoS One (2012) 0.93
Hepatitis B ESL education for Asian immigrants. J Community Health (2011) 0.92
Evidence and knowledge gaps on the disease burden in sexual and gender minorities: a review of systematic reviews. Int J Equity Health (2016) 0.92
Enigmatic origin of hepatitis B virus: an ancient travelling companion or a recent encounter? World J Gastroenterol (2014) 0.91
Hepatitis B virus burden in developing countries. World J Gastroenterol (2015) 0.91
Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood (2014) 0.90
Modeling the adaptive immune response in HBV infection. J Math Biol (2011) 0.90
Evaluation of a hepatitis B educational ESL curriculum for Chinese immigrants. Can J Public Health (2010) 0.90
Risk factors for retrovirus and hepatitis virus infections in accepted blood donors. Transfusion (2014) 0.89
Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic. J Viral Hepat (2010) 0.89
Meta-analysis of the clinical value of danshen injection and huangqi injection in liver cirrhosis. Evid Based Complement Alternat Med (2013) 0.88
Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. World J Gastroenterol (2013) 0.88
Host susceptibility to persistent hepatitis B virus infection. World J Gastroenterol (2006) 0.88
Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth. Hum Genet (2009) 0.87
Lamivudine treatment and outcome in pregnant women with high hepatitis B viral loads. Eur J Clin Microbiol Infect Dis (2014) 0.87
Seroepidemiology of hepatitis B virus infection: analysis of mass screening in Hawaii. Hepatol Int (2008) 0.87
Hepatitis B knowledge, screening, and vaccination among Hmong Americans. J Health Care Poor Underserved (2013) 0.86
Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. J Hepatol (2014) 0.85
Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol Int (2009) 0.85
Risk of pancreatic cancer among individuals with hepatitis C or hepatitis B virus infection: a nationwide study in Sweden. Br J Cancer (2013) 0.85
A cross-border comparison of hepatitis B testing among chinese residing in Canada and the United States. Asian Pac J Cancer Prev (2009) 0.84
Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment. Pediatrics (2013) 0.83
Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol (2014) 0.83
Epidemiology of hepatitis B--clinical implications. MedGenMed (2006) 0.83
Association Between Chronic Hepatitis B Virus Infection and Risk of Osteoporosis: A Nationwide Population-Based Study. Medicine (Baltimore) (2015) 0.82
Interleukin-16 gene polymorphisms are considerable host genetic factors for patients' susceptibility to chronic hepatitis B infection. Hepat Res Treat (2014) 0.82
Hepatitis B among Pacific Islanders in Southern California: how is health information associated with screening and vaccination? J Community Health (2011) 0.82
Complex association between alanine aminotransferase activity and mortality in general population: a systematic review and meta-analysis of prospective studies. PLoS One (2014) 0.82
Improved Efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients. Medicine (Baltimore) (2015) 0.82
A Survey Study of Pregnant Women and Healthcare Practitioners Assessing the Knowledge of Attitudes and Practices of Hepatitis B Management at a Teaching Hospital in Kumasi, Ghana, West Africa. Open Forum Infect Dis (2015) 0.82
Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010. PLoS One (2013) 0.81
Can Serum ST2 Levels Be Used as a Marker of Fibrosis in Chronic Hepatitis B Infection? Medicine (Baltimore) (2015) 0.81
Impact of universal vaccination against hepatitis B: the italian model. Hepat Mon (2012) 0.81
Segmental difference of the hepatic fibrosis from chronic viral hepatitis due to hepatitis B versus C virus infection: comparison using dual contrast material-enhanced MRI. Korean J Radiol (2011) 0.81
The loss of HBeAg without precore mutation results in lower HBV DNA levels and ALT levels in chronic hepatitis B virus infection. J Gastroenterol (2009) 0.81
Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure. PLoS One (2012) 0.81
Circulating miR-583 and miR-663 Refer to ZHENG Differentiation in Chronic Hepatitis B. Evid Based Complement Alternat Med (2013) 0.81
Serum complement C4b, fibronectin, and prolidase are associated with the pathological changes of pulmonary tuberculosis. BMC Infect Dis (2014) 0.81
The survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis B virus infection and cirrhosis. PLoS One (2012) 0.80
Prevalence of hepatitis B surface antigen (HBsAg) and its risk factors among individuals visiting Goba General Hospital, South East Ethiopia, 2012. BMC Res Notes (2014) 0.80
Hepatitis B virus DNA level Among the Seropositive Afghan Immigrants, Southern Iran. Jundishapur J Microbiol (2014) 0.80
Distribution Characteristics of Hepatitis B Serological Markers in Hospitalized Children and Adolescents in Zhejiang, China between 2006 and 2010. Gut Liver (2011) 0.80
Community-based hepatitis B screening: what works? Hepatol Int (2014) 0.80
Role of KIR genes and genotypes in susceptibility to or protection against hepatitis B virus infection in a Turkish cohort. Med Sci Monit (2014) 0.80
The Role of Immune Cells in Chronic HBV Infection. J Clin Transl Hepatol (2015) 0.80
New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia. PLoS One (2014) 0.79
A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. Hepatol Int (2011) 0.79
MicroRNA panels as disease biomarkers distinguishing hepatitis B virus infection caused hepatitis and liver cirrhosis. Sci Rep (2015) 0.79
Single-nucleotide polymorphism at CYP27B1-1260, but not VDR Taq I, is possibly associated with persistent hepatitis B virus infection. Genet Test Mol Biomarkers (2012) 0.79
A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. PLoS One (2013) 0.79
Viral hepatitis in Hawai'i--differing perspectives. Hawaii Med J (2010) 0.78
Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. World J Gastroenterol (2011) 0.78
CD34+ hematopoietic stem cells mobilization, paralleled with multiple cytokines elevated in patients with HBV-related acute-on-chronic liver failure. Dig Dis Sci (2012) 0.78
NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure. PLoS One (2015) 0.78
Hepatitis B among Asian Americans: Prevalence, progress, and prospects for control. World J Gastroenterol (2015) 0.78
Long-term follow-up and suboptimal treatment rates of treatment-eligible chronic hepatitis B patients in diverse practice settings: a gap in linkage to care. BMJ Open Gastroenterol (2015) 0.78
Low treatment rates in patients meeting guideline criteria in diverse practice settings. Dig Dis Sci (2014) 0.77
Human immunodeficiency virus and viral hepatitis among high-risk groups: Understanding the knowledge gap in the Middle East and North Africa Region. World J Hepatol (2015) 0.77
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet (2007) 10.12
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med (2009) 9.38
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med (2005) 7.61
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Expenditures and health status among adults with back and neck problems. JAMA (2008) 6.11
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
A randomized trial of epidural glucocorticoid injections for spinal stenosis. N Engl J Med (2014) 5.01
The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med (2015) 4.75
Rapid magnetic resonance imaging vs radiographs for patients with low back pain: a randomized controlled trial. JAMA (2003) 4.52
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health (2007) 3.93
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52
Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm (2003) 3.34
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75
The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD (2005) 2.66
Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care (2008) 2.64
The coming epidemic of obesity in elderly Americans. J Am Geriatr Soc (2004) 2.55
Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med (2013) 2.54
Warfarin pharmacogenetics. Pharmacotherapy (2008) 2.50
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol (2013) 2.44
Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med (2002) 2.43
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
Cardiovascular events associated with ipratropium bromide in COPD. Chest (2009) 2.36
Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care (2003) 2.33
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 2.28
Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. Med Care (2006) 2.28
Can we reliably benchmark health technology assessment organizations? Int J Technol Assess Health Care (2012) 2.27
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl (2002) 2.25
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics (2010) 2.19
Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis (2012) 2.19
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm (2015) 2.15
Incidence of minor complications and time lost from normal activities after screening or surveillance colonoscopy. Gastrointest Endosc (2006) 2.14
The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report. Value Health (2003) 2.07
Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol (2004) 2.03
Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy (2014) 2.02
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction. J Pediatr (2002) 1.96
Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res (2012) 1.91
The North American Study for the Treatment of Refractory Ascites. Gastroenterology (2003) 1.87
The impact of computerized provider order entry on medication errors in a multispecialty group practice. J Am Med Inform Assoc (2010) 1.85
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy (2010) 1.83
Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med (2003) 1.79
An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost (2008) 1.76
Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations? Int J Technol Assess Health Care (2010) 1.70
Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Med Decis Making (2013) 1.70
Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm (2015) 1.67
The impact of e-prescribing on prescriber and staff time in ambulatory care clinics: a time motion study. J Am Med Inform Assoc (2007) 1.64
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision. Ann Surg (2011) 1.63
Identification of differentially expressed genes in response to dietary iron deprivation in rat duodenum. Am J Physiol Gastrointest Liver Physiol (2005) 1.63
Medicaid prior authorization and controlled-release oxycodone. Med Care (2008) 1.61
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Hereditary hemochromatosis: time for targeted screening. Ann Intern Med (2008) 1.60
Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol (2010) 1.60
Improving pediatric asthma outcomes in the community setting: does pharmaceutical care make a difference? J Am Pharm Assoc (Wash) (2002) 1.59
Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transpl (2006) 1.59
A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med (2012) 1.58
Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol (2007) 1.58
Resource costs for asthma-related care among pediatric patients in managed care. Ann Allergy Asthma Immunol (2003) 1.57
Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J Lipid Res (2011) 1.54
A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics. Genet Med (2012) 1.52
Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs (2013) 1.50
Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease. J Allergy Clin Immunol (2007) 1.50
Complications after ERCP in patients with primary sclerosing cholangitis. Gastrointest Endosc (2007) 1.49
Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology (2003) 1.48
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making (2010) 1.45
Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study. Pediatr Allergy Immunol (2006) 1.45
Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model. Acad Radiol (2011) 1.45
The timing of elective colectomy in diverticulitis: a decision analysis. J Am Coll Surg (2004) 1.45
Comparison of guideline-based control definitions and associations with outcomes in severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol (2008) 1.44
The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes. Ann Allergy Asthma Immunol (2004) 1.44
Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genomics (2006) 1.44
Optimizing CAD diagnosis in China with CT angiography. J Cardiovasc Comput Tomogr (2009) 1.43
The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa. Ann Pharmacother (2009) 1.42
The management of chronic hepatitis B in Asian Americans. Dig Dis Sci (2011) 1.42
Patients' experience and outcomes after laparoscopic adjustable gastric banding in Washington state. Surg Obes Relat Dis (2012) 1.42
Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study. Liver Int (2007) 1.42
Iron overload related to excessive vitamin C intake. Ann Intern Med (2003) 1.41
Neuroleptic drug exposure and incidence of tardive dyskinesia: a records-based case-control study. J Manag Care Pharm (2003) 1.40
Abnormal liver test results on routine screening. How to evaluate, when to refer for a biopsy. Postgrad Med (2004) 1.39
Response to Wolf [corrected] and Marks. J Allergy Clin Immunol (2005) 1.39